What might be the future applications for BCMA-directed bispecific antibodies in MM and other PCD?

The Multiple Myeloma Hub spoke with Sagar Lonial, Winship Cancer Institute of Emory University, Atlanta, US. We asked, What might be the future applications for B-cell maturation antigen (BCMA)-directed bispecific antibodies in multiple myeloma (MM) and other plasma cell dyscrasias?In this interview, Sagar Lonial discussed the expanding role of BCMA-directed bispecific antibody therapies beyond relapsed/refractory MM, including their potential applications in high-risk smoldering MM and light-chain (AL) amyloidosis. Lonial also evaluated emerging strategies for optimizing dosing schedules, enhancing the patient experience, and mitigating treatment resistance.This educational resource is independently supported by Johnson & Johnson. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence on the content of this resource.  Hosted on Acast. See acast.com/privacy for more information.